Chang Yun-Li, Zhou Pei-Jie, Wei Lianzi, Li Wang, Ji Zhongzhong, Fang Yu-Xiang, Gao Wei-Qiang
State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
School of Biomedical Engineering & Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200030, China.
Oncotarget. 2015 Sep 15;6(27):24017-31. doi: 10.18632/oncotarget.4447.
Up to now, the molecular mechanisms underlying the stemness of prostate cancer stem cells (PCSCs) are still poorly understood. In this study, we demonstrated that microRNA-7 (miR-7) appears to be a novel tumor-suppressor miRNA, which abrogates the stemness of PCSCs and inhibits prostate tumorigenesis by suppressing a key stemness factor KLF4. MicroRNA-7 is down-regulated in prostate cancer cells compared to non-tumorigenic prostate epithelial cells. Restoration of miR-7 suppresses the expression of the stemness factor KLF4 in PCSCs and inhibits prostate tumorigenesis both in vitro and in vivo. Interestingly, the suppression of the stemness of PCSCs by miR-7 is sustained for generations in xenografts. Analysis of clinical samples also revealed a negative correlation between miR-7 expression and prostate tumor progression. Mechanistically, overexpression of miR-7 may lead to a cell cycle arrest but not apoptosis, which seems achieved via suppressing the KLF4/PI3K/Akt/p21 pathway. This study identifies miR-7 as a suppressor of PCSCs' stemness and implicates its potential application for PCa therapy.
到目前为止,前列腺癌干细胞(PCSCs)干性的分子机制仍知之甚少。在本研究中,我们证明了微小RNA-7(miR-7)似乎是一种新型的肿瘤抑制性微小RNA,它通过抑制关键的干性因子KLF4消除PCSCs的干性并抑制前列腺肿瘤发生。与非致瘤性前列腺上皮细胞相比,微小RNA-7在前列腺癌细胞中表达下调。miR-7的恢复抑制了PCSCs中干性因子KLF4的表达,并在体外和体内抑制前列腺肿瘤发生。有趣的是,miR-7对PCSCs干性的抑制在异种移植中可维持几代。临床样本分析还显示miR-7表达与前列腺肿瘤进展呈负相关。从机制上讲,miR-7的过表达可能导致细胞周期停滞而非凋亡,这似乎是通过抑制KLF4/PI3K/Akt/p21途径实现的。本研究确定miR-7为PCSCs干性的抑制剂,并暗示其在前列腺癌治疗中的潜在应用。